Neurotrack Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurotrack Technologies, Inc.
Neurotrack Technologies revises website “to ensure that its communications better align with its evidence-backed offerings” following a National Advertising Division review of an advertising challenge by Posit Science.
With Alzheimer’s researchers now looking to head off the disease in its earlier stages, the hunt is on for ways to detect its presence when patients aren’t necessarily showing symptoms. Neurotrack Technologies Inc. is building a noninvasive eye-tracking test that it believes could replace the ADAS-COG battery of neurological tests that are the current front line of diagnosis of the disease.
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
- Digital Health
- In Vitro Diagnostics
- Other Names / Subsidiaries
- Neurotrack Technologies Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.